Human SLC35C2 activation kit by CRISPRa

CAT#: GA109491

SLC35C2 CRISPRa kit - CRISPR gene activation of human solute carrier family 35 member C2



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

经常一起买 (3)
Rabbit Polyclonal Anti-Slc35c2 Antibody
    • 100 ul

CNY 5,250.00


SLC35C2 (Myc-DDK-tagged)-Human solute carrier family 35, member C2 (SLC35C2), transcript variant 3
    • 10 ug

CNY 3,656.00
CNY 3,990.00


SLC35C2 Antibody - C-terminal region
    • 100 ul

CNY 5,250.00

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol SLC35C2
Locus ID 51006
Kit Components

GA109491G1, SLC35C2 gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA109491G2, SLC35C2 gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA109491G3, SLC35C2 gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_001281457, NM_001281458, NM_001281459, NM_001281460, NM_015945, NM_173073, NM_173179
Synonyms BA394O2.1; C20orf5; CGI-15; OVCOV1
Summary This gene encodes a member of the triose-phosphate transporter protein family. This gene is regulated by oxygen tension, is induced in hypoxic trophoblast cells, and is overexpressed in ovarian cancer. Alternative splicing results in multiple transcript variants. A pseudogene of this gene has been defined on the X chromosome. [provided by RefSeq, Jul 2013]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...